VivoSeq
Oncology

Esophageal Squamous Cell Carcinoma (ESCC)

2

Pipeline Programs↗

5

Active Trials↗

2

Companies Involved↗

Esophageal Squamous Cell Carcinoma (ESCC) is an early-stage landscape with 2 programs across 2 companies. The most active players are Bristol-Myers Squibb, Avyxa.

Intelligence

Pipeline Metrics

Competitive Density

25/100

Pipeline Velocity

19/100

Mech. Concentration

N/A

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Bristol-Myers Squibb logo

Bristol-Myers Squibb

1 program

Phase 2A

Avyxa

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 22

Albumin-Bound Paclitaxel

Bristol-Myers Squibb

Carboplatin

Avyxa

Phase 3
No programs
Approved
No programs

Analysis

Trial Status

5

clinical trials

Not yet recruiting2 · 40%
Active, not recruiting2 · 40%
Recruiting1 · 20%

Clinical Trials

Trial Activity

Tumor-Draining Lymph Node Preservation-Guided Intraoperative Lymphadenectomy After Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell Carcinoma: A Prospective Multicenter Observational Cohort Study
Not yet recruiting·TTongji Hospital·N/A·NCT07697898·400 enrolled
Biomarkers for Predicting Response to PD-1 Inhibitor Therapy in Squamous Cell Carcinoma: A Retrospective-Prospective Cohort Study
Active, not recruiting·CCancer Institute and Hospital, Chinese Academy of Medical Sciences·N/A·NCT07147361·800 enrolled
A Phase III Randomized Controlled Study Investigating the Combination of PD-1 Inhibitors With Local Therapy Administered at Distinct Treatment Timings Among Patients With Oligometastatic Esophageal Squamous Cell Carcinoma
Recruiting·FFudan University·N/A·NCT07697859·354 enrolled
Low-Dose Radiotherapy Combined With Retlirafusp Alfa and Chemotherapy as Neoadjuvant Therapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma: An Exploratory Phase II Study
Active, not recruiting·HHarbin Medical University·Phase 2·NCT07682376·96 enrolled
Neoadjuvant Short-Course Radiotherapy Followed by Tislelizumab Combined With Chemotherapy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma: A Prospective, Multicenter, Exploratory Study
Not yet recruiting·TTang-Du Hospital·Phase 2·NCT07678580·50 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)